Mesoblast (MESO) Cash & Equivalents Growth (1y) (2016 - 2025)

Mesoblast (MESO) Cash & Equivalents Growth (1y) (2016 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 23.56%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 23.05%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 71.81%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 84.98%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 10.29%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 28.50%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 53.39%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -57.58%
10 Mesoblast 2.01 Bn 1.87 Bn - 241.78%

Historic Data

Download Data
DateValue
Dec 31, 2025 241.78%
Jun 30, 2025 156.59%
Dec 31, 2024 -50.96%
Jun 30, 2024 -11.72%
Dec 31, 2023 14.69%
Jun 30, 2023 17.98%
Mar 31, 2023 -36.43%
Dec 31, 2022 -28.71%
Sep 30, 2022 -26.26%
Jun 30, 2022 -55.84%
Mar 31, 2022 -51.50%
Dec 31, 2021 22.34%
Sep 30, 2021 7.24%
Jun 30, 2021 5.84%
Mar 31, 2021 163.43%
Dec 31, 2020 -4.70%
Sep 30, 2020 213.07%
Jun 30, 2020 156.47%
Mar 31, 2020 -14.65%
Dec 31, 2019 5.62%